Category: News

News

Novartis Ianalumab Clinches FDA Breakthrough Status, Aiming to Be First Targeted Treatment for Sjögren’s Disease

novartis

Novartis reaches a historic milestone in immunology as the FDA grants Breakthrough Therapy designation to ianalumab for Sjögren’s disease. Backed by successful Phase III NEPTUNUS trials, this dual-action monoclonal antibody is poised to become the first targeted therapy for this chronic autoimmune condition. With global regulatory submissions planned for early 2026, ianalumab represents a significant leap forward for millions of patients currently facing an immense unmet medical need.

Clinical Trials Healthcare & Pharmaceuticals News Oncology

Johnson & Johnson Announces Landmark Phase 3 Results: TECVAYLI® Reduces Risk of Disease Progression or Death by 71% in Early Relapse Multiple Myeloma

JohnsonAndJohnson

Johnson & Johnson (NYSE: JNJ) today announced groundbreaking topline results from the Phase 3 MajesTEC-9 study, demonstrating that TECVAYLI® (teclistamab-cqyv) monotherapy significantly improves outcomes for [Read More…]

Artificial Intelligence Drug Discovery Healthcare & Pharmaceuticals News

NVIDIA and Lilly Unveil $1 Billion AI Lab to Revolutionize Drug Discovery

Eli Lilly and Company

NVIDIA and Eli Lilly have unveiled a landmark $1 billion partnership to launch a first-of-its-kind AI co-innovation lab in the San Francisco Bay Area. By co-locating world-class scientists and AI engineers, the collaboration aims to “industrialize” drug discovery through advanced foundation models, robotics, and “lab-in-a-loop” workflows.

Anti-obesity Drugs Business Healthcare & Pharmaceuticals News

Novo Nordisk Launches Oral Wegovy®, Marked as First-Ever GLP-1 Weight Loss Pill Available in the U.S.

Wegovy pill

Novo Nordisk has officially launched the Wegovy® pill, the first-ever oral GLP-1 medication for weight management in adults. Following FDA approval in late 2025, this once-daily pill offers a needle-free alternative to injections, demonstrating an average weight loss of up to 17% in clinical trials. With tiered pricing starting at $149 per month for self-pay patients, oral Wegovy is now available through major U.S. pharmacies and select telehealth platforms.

Business News

Johnson & Johnson Completes $3.05 Billion Acquisition of Halda Therapeutics to Advance Next-Gen Cancer Care

JohnsonAndJohnson

Johnson & Johnson has finalized a landmark $3.05 billion acquisition of Halda Therapeutics, integrating the clinical-stage biotech’s proprietary RIPTACâ„¢ platform. This strategic move adds HLD-0915—a next-generation oral therapy for prostate cancer to J&J’s portfolio, signaling a major shift toward precision, “cell-killing” mechanisms designed to overcome traditional treatment resistance.